TBC1D22A and ovarian cancer: Further analysis showed that ovarian cancer patients with high level of CITED2, LYVE1, OGN, RAP1A, and TBC1D22A had a poor prognosis that that with level of CITED2, LYVE1, OGN, RAP1A, and TBC1D22A (Supplementary Fig. 5B, all p < 0.05).